- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Mary Schroth Discusses At-Home Treatment Options for Patients With SMA
Increasing at-home access to care and treatment options for spinal muscular atrophy (SMA) proved to be helpful during the coronavirus disease 2019 (COVID-19) pandemic, explained Mary Schroth, MD, FAAP, FCCP, chief medical officer at Cure SMA.
The latest FDA approved treatment is Evrysdi, which is an oral at-home therapy. What are the benefits of having this additional therapy available?
The FDA approval of Evrydi (risdiplam) plan provides another treatment option for people living with SMA. The ability to take a medication at home and by mouth or feeding tube will allow more people access to an SMA treatment. With multiple treatments for us to may available, patients should work in consultation with their health care provider team to determine which treatment option is best for their specific needs.
How has the COVID-19 pandemic affected people with SMA and their caregivers? For instance, are they more at risk of getting infected? Do we know what impact the virus has if they do get COVID-19?
Per feedback from our community about COVID-19, we learned that COVID-19 temporarily interfered with patients being able to receive treatments as scheduled. Monitory care transitioned to more telemedicine delivery and providing care in-person when necessary. Similarly, clinical trial visits have been modified to conduct in-person visits when essential, and other visits were modified to be conducted virtually.
We have limited reports of people living with us may have actually having COVID-19. In general, people living with SMA avoid others who are sick. And during the winter viral season, they already were avoiding public contact as much as possible. There's not enough information available to make any conclusions about the impact of infection on those with SMA. We surveyed our SMA community and we learned that less than 5% actually had COVID-19 infection or symptoms of COVID-19.
AI in Health Care: Closing the Revenue Cycle Gap
April 1st 2025This commentary explores the current state, challenges, and potential of artificial intelligence (AI) in health care revenue cycle management, emphasizing collaboration, data standardization, and targeted implementation to enhance adoption.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More
